Lapitinib is used in conjunction with capecitabine.
- TRADE NAME: Tykerb (Novartis)
- INDICATIONS: Breast cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Epidermal growth factor receptor (EGFR) inhibitor / antagonist, HER2/neu receptor antagonist (HER2 receptor antagonist), Tyrosine kinase inhibitor
- HALF-LIFE: 24 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfuzosin, Artemether/Lumefantrine, Atazanavir, Carbamazepine, Chloroquine, Ciprofloxacin, Clarithromycin, Clozapine, Colchicine, Conivaptan, CYP2C8 substrates, CYP3A4 inhibitors or inducers, Dabigatran, Deferasirox, Dexamethasone, Digoxin, Docetaxel, Dronedarone, Efavirenz, Eplerenone, Everolimus, Fentanyl, Food, Gadobutrol, Grapefruit Juice, Histamine H2-antagonists, Indinavir, Irinotecan, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Nilotinib, Omeprazole, P-glycoprotein inducers, Paclitaxel, Pantoprazole, Pazopanib, Phenobarbital, Phenytoin, Pimecrolimus, Pimozide, Posaconazole, Proton pump inhibitors, QT prolonging agents, Quinine, Repaglinide, Rifabutin, Rifampin, Rifapentin, Ritonavir, Rivaroxaban, Safinamide, Salmeterol, Saquinavir, Saxagliptin, Silodosin, St John's Wort, Telithromycin, Tetrabenazine, Thioridazine, Tolvaptan, Topotecan, Voriconazole, Ziprasidone
HEPATOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of lapatinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
